Back to search

Netherlands· NL-19fd19aa1d20

Doxorubicine hydrochloride 2 mg/ml PCH, concentraat voor oplossing voor infusie

A doxorubicin product containing doxorubicinehydrochloride, registered in Netherlands by Pharmachemie B.V.. The same ATC class is registered in 17 of our 19 countries.

ATC L01DB01

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedDoxorubicine hydrochloride 2 mg/ml PC…ATCL01DB01REGISTER NO.NL-19fd19aa1d20PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Doxorubicin is registered in 17 of 19 countries.

Countries holding a registration under ATC L01DB01 (doxorubicin), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 10 of them publish a price we can compare per daily dose

Doxorubicin · ATC L01DB01

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of doxorubicin costs, country by country.

Normalised to the WHO defined daily dose (5 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Doxorubicin · price per daily dose (5 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$12.19
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
DOXORUBICINEHYDROCHLORIDE
Manufacturer
Pharmachemie B.V.
Country
Netherlands (NL)
ATC code
L01DB01
ATC class
Doxorubicin
Defined daily dose
5 mg, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    102758

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

775 interactions on record for doxorubicin.

Graded by severity as the source publishes them — 98 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Doxorubicin · interactions on record

775 records

  • 98 severe
  • 383 moderate
  • 29 minor
  • 265 info

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • QuinidineC01BA01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Doxorubicin in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All doxorubicin products

Authorised across Europe · EMA

The same active substance is authorised in 30 EEA countries. Names it is sold under:

  • Austria · Adriblastin, Doxorubicin Accord
  • Belgium · Adriblastina Ready To Use, Doxorubicin Accord Healthcare
  • Bulgaria · Доксорубицин Акорд
  • Cyprus · Adriblastina
  • Czechia · Doxorubicin Ebewe, Doxorubicin Medac
  • Germany · Adriacept Blasen-Instillations-Set, Adrimedac
  • Denmark · Adriamycin, Doxorubicin Accord
  • Estonia · Doxorubicin Accord
  • Spain · Doxorubicina Accord, Doxorubicina Aurovitas
  • Finland · Doxorubicin Accord, Doxorubicin Medac
  • France · Adriblastine, Doxorubicin Teva
  • United Kingdom (Northern Ireland) · Doxorubicin Accord Healthcare, Doxorubicin Hydrochloride Medac
  • Greece · Adriblastina, Doxiprol
  • Croatia · Doxorubicin Pliva, Sindroxocin
  • Hungary · Doxorubicin Accord, Doxorubicin Sandoz
  • Ireland · Doxorubicin Accord Healthcare Ireland, Doxorubicin Rivopharm
  • Iceland · Caelyx Pegylated Liposomal, Doxorubicin Medac
  • Italy · Adriblastina, Doxorubicin Teva
  • Liechtenstein · Caelyx Pegylated Liposomal, Myocet Liposomal
  • Lithuania · Doxorubicin Accord, Doxorubicin Ebewe
  • Luxembourg · Adriblastina Ready To Use, Doxorubicine Teva
  • Latvia · Doxorubicin Accord
  • Malta · Doxorubicin Accord Healthcare
  • Norway · Adriamycin, Caelyx Pegylated Liposomal
  • Poland · Doxorubicin Ebewe, Doxorubicinum Accord
  • Portugal · Doxorrubicina Accord, Doxorrubicina Aurovitas
  • Romania · Doxlox, Doxorubicină Accord
  • Sweden · Doxorubicin Accord, Doxorubicin Ebewe
  • Slovenia · Doksorubicin Accord, Doksorubicin Sandoz
  • Slovakia · Doxorubicin Medac, Doxorubicin Sandoz

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e06b23c4-1dbc-4120-bbb8-72f20e76e1d9
GET /v1/drugs/e06b23c4-1dbc-4120-bbb8-72f20e76e1d9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Concentraat voor oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h102758_smpc.pdf",
  "strength": null,
  "atc_label": "Doxorubicin",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg102758",
  "excipients": [
    "NATRIUMCHLORIDE",
    "NATRIUMHYDROXIDE (E 524)",
    "STIKSTOF (HEAD SPACE) (E 941)",
    "WATER VOOR INJECTIE",
    "ZOUTZUUR (E 507)"
  ],
  "substances": [
    "DOXORUBICINEHYDROCHLORIDE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h102758.pdf",
  "authorised_at": "2010/07/07",
  "procedure_number": "NL/H/1403/001",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "102758",
  "additional_monitoring": "N"
}

See everything about doxorubicin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.